6月1日，映恩生物-B盘中下跌5.59%，报213.0港元/股，成交额1.52亿港元。
映恩生物-B所在的生物科技行业中，板块表现分化，个股中，康方生物涨2.37%，三生制药涨1.14%，信达生物跌2.64%，百济神州跌2.32%，科伦博泰生物跌3.25%。
映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324等，用于靶向治疗多种实体瘤。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.